GILEAD SCIENCES, INC. (GILD) FY2024 Q3 P&L / Income Statement

Income StatementCash FlowBalance Sheet

Revenue by Product and Service by Geography

2024-07-01 to 2024-09-30

Swipe to see the full flow
GILEAD SCIENCES, INC. (GILD) FY2024 Q3 P&L / Income StatementIncome statement for 2024-07-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETProduct sales - UNITED STATESTotal HIV - UNITED STATESBiktarvy - UNITED STATESProduct sales - EuropeProduct sales - Rest of WorldTotal HIV - EuropeDescovy - UNITED STATESTotal Oncology - UNITED STATESTotal Liver Disease - UNITED STATESVeklury - UNITED STATESGenvoya - UNITED STATESBiktarvy - EuropeTotal HIV - Rest of WorldTotal Oncology - EuropeBiktarvy - Rest of WorldOdefsey - UNITED STATESTrodelvy - UNITED STATESSofosbuvir/Velpatasvir - UNITED STATESVeklury - Rest of WorldTotal Cell Therapy - EuropeTotal Cell Therapy - UNITED STATESTotal Liver Disease - Rest of WorldYescarta - EuropeYescarta - UNITED STATESTotal Liver Disease - EuropeVemlidy - UNITED STATESSymtuza - Revenue share - UNITED STATESSofosbuvir/Velpatasvir - Rest of WorldVemlidy - Rest of WorldTotal Oncology - Rest of WorldVeklury - EuropeTotal Other - EuropeTrodelvy - EuropeAmBisome - EuropeOdefsey - EuropeTotal Other - Rest of WorldSofosbuvir/Velpatasvir - EuropeTotal Cell Therapy - Rest of WorldTecartus - UNITED STATESYescarta - Rest of WorldTotal Other - UNITED STATESAmBisome - Rest of WorldGenvoya - EuropeSymtuza - Revenue share - EuropeTecartus - EuropeDescovy - Rest of WorldTrodelvy - Rest of WorldDescovy - EuropeGenvoya - Rest of WorldRoyalty, contract and other revenues - UNITED STATESRoyalty, contract and other revenues - EuropeVemlidy - EuropeOdefsey - Rest of WorldTecartus - Rest of WorldAmBisome - UNITED STATESSymtuza - Revenue share - Rest of WorldRoyalty, contract and other revenues - Rest of WorldOther HIV - UNITED STATESOther Liver Disease - EuropeOther - UNITED STATESOther Liver Disease - UNITED STATESOther HIV - EuropeOther Liver Disease - Rest of WorldOther - Rest of WorldOther HIV - Rest of WorldOther - EuropeTotal revenuesRevenue before reconciliation (calculated)Components above reported revenue (calculated)Gross profit (calculated)Cost of goods soldOperating income (loss)Operating expenses (calculated)In-process research and development impairmentSelling, general and administrative expensesResearch and development expensesAcquired in-process research and development expensesOther income (expense), net (calculated)Income (loss) before income taxesNet income (loss)Income tax (benefit) expenseIncome tax (benefit) expenseIncome tax(benefit) expense−$297.00 MOther income (expense), net (calculated)Other income,net (calculated)$68.00 MRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$22.37 BIncome (loss) before income taxesIncome (loss)before income taxes$956.00 MGross profit (calculated)Gross profit(calculated)$5.97 BOperating income (loss)Operatingincome (loss)$888.00 MTotal revenuesTotal revenues$7.55 BNet income (loss)Net income (loss)$1.25 BProduct sales - UNITED STATESProduct sales -UNITED STATES$5.43 BOperating expenses (calculated)Operating expenses(calculated)$5.08 BIn-process research and development impairmentIn-process research anddevelopment impairment$1.75 BTotal HIV - UNITED STATESTotal HIV -UNITED STATES$4.16 BCost of goods soldCost of goods sold$1.57 BSelling, general and administrative expensesSelling, general andadministrative expenses$1.43 BBiktarvy - UNITED STATESBiktarvy -UNITED STATES$2.83 BResearch and development expensesResearch anddevelopment expenses$1.40 BProduct sales - EuropeProduct sales - Europe$1.15 BProduct sales - Rest of WorldProduct sales- Rest of World$928.00 MAcquired in-process research and development expensesAcquired in-process researchand development expenses$505.00 MComponents above reported revenue (calculated)Components abovereported revenue(calculated)−$14.82 BTotal HIV - EuropeTotal HIV - Europe$570.00 MDescovy - UNITED STATESDescovy -UNITED STATES$534.00 MTotal Oncology - UNITED STATESTotal Oncology- UNITED STATES$433.00 MTotal Liver Disease - UNITED STATESTotal Liver Disease- UNITED STATES$393.00 MVeklury - UNITED STATESVeklury -UNITED STATES$393.00 MGenvoya - UNITED STATESGenvoya -UNITED STATES$384.00 MBiktarvy - EuropeBiktarvy - Europe$375.00 MTotal HIV - Rest of WorldTotal HIV -Rest of World$342.00 MTotal Oncology - EuropeTotal Oncology- Europe$291.00 MBiktarvy - Rest of WorldBiktarvy - Rest of World$272.00 MOdefsey - UNITED STATESOdefsey -UNITED STATES$248.00 MTrodelvy - UNITED STATESTrodelvy -UNITED STATES$226.00 MSofosbuvir/Velpatasvir - UNITED STATESSofosbuvir/Velpatasvir- UNITED STATES$222.00 MVeklury - Rest of WorldVeklury - Rest of World$219.00 MTotal Cell Therapy - EuropeTotal CellTherapy - Europe$211.00 MTotal Cell Therapy - UNITED STATESTotal Cell Therapy- UNITED STATES$208.00 MTotal Liver Disease - Rest of WorldTotal Liver Disease- Rest of World$207.00 MYescarta - EuropeYescarta - Europe$182.00 MYescarta - UNITED STATESYescarta -UNITED STATES$145.00 MTotal Liver Disease - EuropeTotal LiverDisease - Europe$132.00 MVemlidy - UNITED STATESVemlidy -UNITED STATES$126.00 MSymtuza - Revenue share - UNITED STATESSymtuza - Revenueshare - UNITED STATES$103.00 MSofosbuvir/Velpatasvir - Rest of WorldSofosbuvir/Velpatasvir- Rest of World$96.00 MVemlidy - Rest of WorldVemlidy - Rest of World$95.00 MTotal Oncology - Rest of WorldTotal Oncology- Rest of World$92.00 MVeklury - EuropeVeklury - Europe$81.00 MTotal Other - EuropeTotal Other - Europe$80.00 MTrodelvy - EuropeTrodelvy - Europe$80.00 MAmBisome - EuropeAmBisome - Europe$71.00 MOdefsey - EuropeOdefsey - Europe$69.00 MTotal Other - Rest of WorldTotal Other -Rest of World$68.00 MSofosbuvir/Velpatasvir - EuropeSofosbuvir/Velpatasvir- Europe$67.00 MTotal Cell Therapy - Rest of WorldTotal Cell Therapy- Rest of World$66.00 MTecartus - UNITED STATESTecartus -UNITED STATES$63.00 MYescarta - Rest of WorldYescarta -Rest of World$60.00 MTotal Other - UNITED STATESTotal Other -UNITED STATES$53.00 MAmBisome - Rest of WorldAmBisome -Rest of World$52.00 MGenvoya - EuropeGenvoya - Europe$44.00 MSymtuza - Revenue share - EuropeSymtuza - Revenueshare - Europe$33.00 MTecartus - EuropeTecartus - Europe$29.00 MDescovy - Rest of WorldDescovy -Rest of World$28.00 MTrodelvy - Rest of WorldTrodelvy -Rest of World$26.00 MDescovy - EuropeDescovy - Europe$24.00 MGenvoya - Rest of WorldGenvoya -Rest of World$21.00 MRoyalty, contract and other revenues - UNITED STATESRoyalty, contractand other revenues- UNITED STATES$17.00 MRoyalty, contract and other revenues - EuropeRoyalty, contractand otherrevenues - Europe$13.00 MVemlidy - EuropeVemlidy - Europe$11.00 MOdefsey - Rest of WorldOdefsey - Rest of World$9.00 MTecartus - Rest of WorldTecartus -Rest of World$6.00 MAmBisome - UNITED STATESAmBisome -UNITED STATES$6.00 MSymtuza - Revenue share - Rest of WorldSymtuza - Revenueshare - Rest of World$3.00 MRoyalty, contract and other revenues - Rest of WorldRoyalty, contractand other revenues- Rest of World$1.00 MOther HIV - UNITED STATESOther HIV -UNITED STATES$65.00 MOther Liver Disease - EuropeOther LiverDisease - Europe$54.00 MOther - UNITED STATESOther - UNITED STATES$47.00 MOther Liver Disease - UNITED STATESOther Liver Disease- UNITED STATES$45.00 MOther HIV - EuropeOther HIV - Europe$26.00 MOther Liver Disease - Rest of WorldOther Liver Disease- Rest of World$17.00 MOther - Rest of WorldOther - Rest of World$16.00 MOther HIV - Rest of WorldOther HIV -Rest of World$9.00 MOther - EuropeOther - Europe$8.00 M
Chart details

GILEAD SCIENCES, INC. (GILD) FY2024 Q3 P&L / Income Statement

Income statement for 2024-07-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues
7,545,000,000 US dollars
Cost of goods sold
1,574,000,000 US dollars
Gross profit (calculated)
5,971,000,000 US dollars
Operating expenses (calculated)
5,083,000,000 US dollars
Operating income (loss)
888,000,000 US dollars
Other income (expense), net (calculated)
68,000,000 US dollars
Income (loss) before income taxes
956,000,000 US dollars
Income tax (benefit) expense
negative 297,000,000 US dollars
Net income (loss)
1,253,000,000 US dollars
Tecartus - UNITED STATES
63,000,000 US dollars
Tecartus - Rest of World
6,000,000 US dollars
Tecartus - Europe
29,000,000 US dollars
Total Cell Therapy - UNITED STATES
208,000,000 US dollars
Total Cell Therapy - Rest of World
66,000,000 US dollars
Total Cell Therapy - Europe
211,000,000 US dollars
Yescarta - UNITED STATES
145,000,000 US dollars
Yescarta - Rest of World
60,000,000 US dollars
Yescarta - Europe
182,000,000 US dollars
Total HIV - UNITED STATES
4,161,000,000 US dollars
Total HIV - Rest of World
342,000,000 US dollars
Total HIV - Europe
570,000,000 US dollars
Biktarvy - UNITED STATES
2,826,000,000 US dollars
Biktarvy - Rest of World
272,000,000 US dollars
Biktarvy - Europe
375,000,000 US dollars
Descovy - UNITED STATES
534,000,000 US dollars
Descovy - Rest of World
28,000,000 US dollars
Descovy - Europe
24,000,000 US dollars
Genvoya - UNITED STATES
384,000,000 US dollars
Genvoya - Rest of World
21,000,000 US dollars
Genvoya - Europe
44,000,000 US dollars
Odefsey - UNITED STATES
248,000,000 US dollars
Odefsey - Rest of World
9,000,000 US dollars
Odefsey - Europe
69,000,000 US dollars
Other HIV - UNITED STATES
65,000,000 US dollars
Other HIV - Rest of World
9,000,000 US dollars
Other HIV - Europe
26,000,000 US dollars
Symtuza - Revenue share - UNITED STATES
103,000,000 US dollars
Symtuza - Revenue share - Rest of World
3,000,000 US dollars
Symtuza - Revenue share - Europe
33,000,000 US dollars
Total Liver Disease - UNITED STATES
393,000,000 US dollars
Total Liver Disease - Rest of World
207,000,000 US dollars
Total Liver Disease - Europe
132,000,000 US dollars
Other Liver Disease - UNITED STATES
45,000,000 US dollars
Other Liver Disease - Rest of World
17,000,000 US dollars
Other Liver Disease - Europe
54,000,000 US dollars
Sofosbuvir/Velpatasvir - UNITED STATES
222,000,000 US dollars
Sofosbuvir/Velpatasvir - Rest of World
96,000,000 US dollars
Sofosbuvir/Velpatasvir - Europe
67,000,000 US dollars
Vemlidy - UNITED STATES
126,000,000 US dollars
Vemlidy - Rest of World
95,000,000 US dollars
Vemlidy - Europe
11,000,000 US dollars
Total Oncology - UNITED STATES
433,000,000 US dollars
Total Oncology - Rest of World
92,000,000 US dollars
Total Oncology - Europe
291,000,000 US dollars
AmBisome - UNITED STATES
6,000,000 US dollars
AmBisome - Rest of World
52,000,000 US dollars
AmBisome - Europe
71,000,000 US dollars
Other - UNITED STATES
47,000,000 US dollars
Other - Rest of World
16,000,000 US dollars
Other - Europe
8,000,000 US dollars
Total Other - UNITED STATES
53,000,000 US dollars
Total Other - Rest of World
68,000,000 US dollars
Total Other - Europe
80,000,000 US dollars
Royalty, contract and other revenues - UNITED STATES
17,000,000 US dollars
Royalty, contract and other revenues - Rest of World
1,000,000 US dollars
Royalty, contract and other revenues - Europe
13,000,000 US dollars
Trodelvy - UNITED STATES
226,000,000 US dollars
Trodelvy - Rest of World
26,000,000 US dollars
Trodelvy - Europe
80,000,000 US dollars
Veklury - UNITED STATES
393,000,000 US dollars
Veklury - Rest of World
219,000,000 US dollars
Veklury - Europe
81,000,000 US dollars
Product sales - UNITED STATES
5,433,000,000 US dollars
Product sales - Rest of World
928,000,000 US dollars
Product sales - Europe
1,154,000,000 US dollars
Selling, general and administrative expenses
1,433,000,000 US dollars
Acquired in-process research and development expenses
505,000,000 US dollars
Research and development expenses
1,395,000,000 US dollars
In-process research and development impairment
1,750,000,000 US dollars
Revenue before reconciliation (calculated)
22,369,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Components above reported revenue (calculated)
negative 14,824,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
GILEAD SCIENCES, INC. (GILD) FY2024 Q3 P&L / Income Statement Sankey chart, Product and service — Product and Service by Geographical view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

79.1%

Gross profit / revenue

Operating margin

11.8%

Operating profit / revenue

Cash conversion

343.9%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!